Timothy Collins - CR Bard Group Pres

Executive

Mr. Timothy P. Collins is Group President of the Company. He joined Bard in 1986 as a facilities planner with the USCI division. Over the next 12 years, Mr. Collins held positions of increasing responsibility including Director of Operations for Diagnostic Cardiology. Concurrent with the sale of Bards cardiology business, Mr. Collins joined Medtronic Vascular in 1998 as Vice PresidentBusiness Unit Manager in MedtronicAVE and was later appointed Vice President, Global Operations, Vascular since 2013.
Age 55
Tenure 11 years
Phone908 277-8000
Webwww.crbard.com
Collins returned to Bard and was President of the Bard Electrophysiology division from 2003 to 2008. In 2008, Mr. Collins was promoted to Group Vice President responsible for worldwide manufacturing operations and also assumed responsibility for the Electrophysiology division, until its sale in November 2013. In January 2012, Mr. Collins assumed additional responsibility for Bard’s businesses in Canada. In July 2013, Mr. Collins was promoted to Group President and assumed additional responsibility for Bard’s businesses in Europe. In July 2015, Mr. Collins assumed additional responsibilities for Bard Medical division.

CR Bard Management Efficiency

CR Bard's management efficiency ratios could be used to measure how well CR Bard manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 1.64 B in debt with debt to equity (D/E) ratio of 81.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. CR Bard has a current ratio of 1.69, which is typical for the industry and considered as normal. Debt can assist CR Bard until it has trouble settling it off, either with new capital or with free cash flow. So, CR Bard's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CR Bard sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BCR to invest in growth at high rates of return. When we think about CR Bard's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Aletha NoonanCDW Corp
N/A
Melanie HouseyPool Corporation
41
Michael DroryCDW Corp
N/A
Kendall LargePool Corporation
N/A
Sara GranackCDW Corp
N/A
Steven OBrienCDW Corp
N/A
Carolyne LargePool Corporation
N/A
Jennifer NeilPool Corporation
50
Ike MihalyPool Corporation
N/A
Kristopher NeffPool Corporation
N/A
Michael BridgfordBridgford Foods
42
Franck BaduelGenuine Parts Co
N/A
Melanie HartPool Corporation
51
Steven RobertsonHanover Foods
67
Donna WilliamsPool Corporation
N/A
Walker SaikPool Corporation
N/A
Timothy BabcoPool Corporation
N/A
Anand RaoCDW Corp
N/A
Chris ColeBridgford Foods
N/A
Scott LeprohonGenuine Parts Co
N/A
Ilya MihalyPool Corporation
N/A
C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard (BCR) is traded on New York Stock Exchange in USA and employs 14,900 people.

Management Performance

CR Bard Leadership Team

Elected by the shareholders, the CR Bard's board of directors comprises two types of representatives: CR Bard inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BCR. The board's role is to monitor CR Bard's management team and ensure that shareholders' interests are well served. CR Bard's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CR Bard's outside directors are responsible for providing unbiased perspectives on the board's policies.
James Beasley, Group President
Patricia Christian, Vice President - Quality, Regulatory and Medical Affairs
Sharon Alterio, Group Vice President
Todd Garner, Vice President - Investor Relations
Marc Breslawsky, Independent Director
John Weiland, President, COO and Director
John DeFord, Senior Vice President - Science, Technology and Clinical Affairs
Frank Lupisella, Principal Accounting Officer, VP and Controller
Betty Larson, Vice President Human Resources.
John Groetelaars, Group Vice President
Tony White, Independent Director
Gerard Porreca, Vice President - Quality, Regulatory and Medical Affairs
Robert Davis, Director
Anthony Welters, Independent Director
Gail Naughton, Independent Director
John Kelly, Independent Director
Tommy Thompson, Independent Director
Samrat Khichi, Senior Vice President General Counsel, Secretary
Sharon Luboff, Group Vice President
Herbert Henkel, Lead Independent Director
Christopher Holland, CFO and Sr. VP
David Melcher, Director
Jim Beasley, Group Pres
Timothy Collins, Group Pres
Timothy Ring, Chairman, CEO and Chairman of Executive Committee
David Barrett, Independent Director

BCR Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CR Bard a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CR Bard in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CR Bard's short interest history, or implied volatility extrapolated from CR Bard options trading.

Pair Trading with CR Bard

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CR Bard position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CR Bard will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Sherwin Williams could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sherwin Williams when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sherwin Williams - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sherwin Williams Co to buy it.
The correlation of Sherwin Williams is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sherwin Williams moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sherwin Williams moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sherwin Williams can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the CR Bard information on this page should be used as a complementary analysis to other CR Bard's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in BCR Stock

If you are still planning to invest in CR Bard check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CR Bard's history and understand the potential risks before investing.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume